Provided by Tiger Trade Technology Pte. Ltd.

Organon & Co

8.21
+0.11001.36%
Post-market: 8.18-0.0269-0.33%19:23 EST
Volume:4.02M
Turnover:33.06M
Market Cap:2.13B
PE:4.29
High:8.43
Open:8.16
Low:7.98
Close:8.10
52wk High:17.23
52wk Low:6.18
Shares:259.98M
Float Shares:258.73M
Volume Ratio:0.82
T/O Rate:1.55%
Dividend:0.34
Dividend Rate:4.14%
EPS(TTM):1.91
EPS(LYR):3.33
ROE:71.62%
ROA:6.40%
PB:2.36
PE(LYR):2.47

Loading ...

Earning Preview: Organon & Co Q4 revenue is expected to decrease by 3.45%, and institutional views are cautious

Earnings Agent
·
Feb 05

Press Release: Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026

Dow Jones
·
Jan 29

Organon & Co. to Report Financial Results and Host Conference Call

Reuters
·
Jan 29

Organon completes divestiture of JADA System to Laborie

TIPRANKS
·
Jan 29

Organon Completes Sale of Jada System to Laborie

MT Newswires Live
·
Jan 29

Organon Completes Divestiture of Jada® System to Laborie

THOMSON REUTERS
·
Jan 29

Organon on Pace for Highest Close Since October 2025 -- Data Talk

Dow Jones
·
Jan 24

Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report

Benzinga_recent_news
·
Jan 20

Organon Says Nexplanon Receives FDA Approval for Extended Use

MT Newswires Live
·
Jan 20

Organon announces U.S. FDA approved sNDA for Nexplanon

TIPRANKS
·
Jan 20

FDA Approves Extended Five-Year Use of Organon's NEXPLANON Contraceptive Implant

Reuters
·
Jan 17

BRIEF-Organon Announces US FDA Approval Of Supplemental New Drug Application Extending Duration Of Use Of Nexplanon® 68 Mg Radiopaque

Reuters
·
Jan 17

Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of Nexplanon® (Etonogestrel Implant) 68 Mg Radiopaque

THOMSON REUTERS
·
Jan 17

Organon & Co - Nexplanon Use Extended to Five Years

THOMSON REUTERS
·
Jan 17

Organon and Co put volume heavy and directionally bearish

TIPRANKS
·
Jan 15

Is Organon (OGN) Quietly Recasting Its Cardiovascular Strategy With the Nilemdo Deal in Northern Europe?

Simply Wall St.
·
Jan 11

Organon to Commercialize Nilemdo in Six European Countries

Reuters
·
Jan 08

Organon Enters Into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway

THOMSON REUTERS
·
Jan 08

Can Organon’s Steep 2025 Share Price Slide Signal a Long Term Opportunity?

Simply Wall St.
·
Dec 12, 2025

Organon Initiated at Underweight by Barclays

Dow Jones
·
Dec 09, 2025